Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): A novel target for an additional therapy

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 4, 2011, Pages 483-498

  Balachandar, S ^a   Katyal, A ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISONE; ARTESUNATE; CHLOROQUINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; MEFLOQUINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PRIMAQUINE; PROGUANIL; QUININE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ANURIA; BRAIN MALARIA; CARDIOTOXICITY; CELL ADHESION; CELL FUNCTION; CHOREA; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSKINESIA; ENDOTHELIUM CELL; EOSINOPHIL COUNT; EXTRAPYRAMIDAL SYMPTOM; FEVER; HEADACHE; HEARING LOSS; HEART VENTRICLE FIBRILLATION; HEMOLYSIS; HUMAN; HYPOGLYCEMIA; IMMUNOMODULATION; KIDNEY CORTEX NECROSIS; MALARIA; MELENA; MICROGLIA; MUSCLE SPASM; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINOPATHY; REVIEW; SPONTANEOUS ABORTION; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; HUMANS; INFLAMMATION; MALARIA, CEREBRAL; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLASMODIUM FALCIPARUM;

EID: 79956049009     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-010-1122-9     Document Type: Review

References (172)

1. Moxon CA, Heyderman RS, Wassmer SC (2009) Dysregulation of coagulation in cerebral malaria. Mol Biochem Parasitol 166:99-108
2. Cox D, McConkey S (2010) The role of platelets in the pathogenesis of cerebral malaria. Cell Mol Life Sci 67:557-568
3. Hora R, Bridges DJ, Craig A, Sharma A (2009) Erythrocytic casein kinase II regulates cytoadherence of Plasmodium falciparum-infected red blood cells. J Biol Chem 284:6260-6269
4. Jurzynski C, Gysin J, Pouvelle B (2007) CD44, a signal receptor for the inhibition of the cytoadhesion of CD36-binding Plasmodium falciparum-infected erythrocytes by CSA-binding infected erythrocytes. Microbes Infect 9:1463-1470 (Pubitemid 350019584)
5. Pouvelle B, Matarazzo V, Jurzynski C, Nemeth J, Ramharter M, Rougon G, Gysin J (2007) Cell adhesion molecule, a new cytoadhesion receptor for Plasmodium falciparum-infected erythrocytes capable of aggregation. Infect Immun 75:3516-3522 (Pubitemid 47040953)
6. Picot S, Bienvenu AL, Konate S, Sissoko S, Barry A, Diarra E, Bamba K, Djimdé A, Doumbo OK (2009) Safety of epoietin-quinine drug combination in children with cerebral malaria in Mali. Malar J 169:8-24
7. Santos-Magalhães NS, Mosqueira VC (2010) Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 18:560-575
8. Odeh M (2001) The role of tumour necrosis factor-alpha in the pathogenesis of complicated falciparum malaria. Cytokine 14:8-11
9. Specht S, Sarite SR, Hauber I, Hauber J, Görbig UF, Meier C, Bevec D, Hoerauf A, Kaiser A (2008) The guanylhydrazone CNI-1493: an inhibitor with dual activity against malaria-inhibition of host cell pro-inflammatory cytokine release and parasitic deoxyhypusine synthase. Parasitol Res 102:1177-1184
10. Singh AP, Surolia N, Surolia A (2009) Triclosan inhibit the growth of the late liver-stage of Plasmodium. IUBMB Life 61:923-928
11. Konieczna A, Lichnovka R, Erdosova B, Ehrmann J (2009) The role of PPARs in MDR - a lesson from embryonic development. Neoplasma 56:279-283
12. Bishop-Bailey D, Bystrom J (2009) Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation. Pharmacol Ther 124:141-150
13. Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernández- López D, Pradillo JM, Caso JR, Vivancos J, Nombela F, Serena J, Lizasoain I, Moro MA (2009) Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPAR gamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 29:3875-3884
14. Ramanan S, Zhao W, Riddle DR, Robbins ME (2010) Role of PPARs in radiation-induced brain injury. PPAR Res 234:975
15. Lin J, Chen A (2008) Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest 88:529-540 (Pubitemid 351581455)
16. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M (2010) Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 59:521-530
17. Gimenez F, Barraud de Lagerie S, Fernandez C, Pino P, Mazier D (2003) Tumor necrosis factor alpha in the pathogenesis of cerebral malaria. Cell Mol Life Sci 60:1623-1635 (Pubitemid 37041361)
18. Reimer T, Shaw MH, Franchi L, Coban C, Ishii KJ, Akira S, Horii T, Rodriguez A, Núñez G (2010) Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome. Eur J Immunol 40:64-69
19. Butthep P, Wanram S, Pattanapanyasat K, Vattanaviboon P, Fucharoen S, Wilairat P (2006) Cytoadherence between endothelial cells and P. falciparum infected and noninfected normal and thalassemic red blood cells. Cytom B Clin Cytom 70:432-442 (Pubitemid 44652080)
20. Howard RJ, Handunnetti SM, Hasler T, Gilladoga A, de Aguiar JC, Pasloske BL, Morehead K, Albrecht GR, van Schravendijk MR (1990) Surface molecules on Plasmodium falciparum-infected erythrocytes involved in adherence. Am J Trop Med Hyg 43:15-29 (Pubitemid 20259479)
21. Weinberg JB, Lopansri BK, Mwaikambo E, Granger DL (2008) Arginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria. Curr Opin Infect Dis 21:468-475
22. Ohnishi K (2009) Cerebral malaria. Brain Nerve 61:122-128
23. Armah H, Dodoo AK, Wiredu EK, Stiles JK, Adjei AA, Gyasi RK, Tettey Y (2005) High-level cerebellar expression of cytokines and adhesion molecules in fatal, paediatric, cerebral malaria. Ann Trop Med Parasitol 99:629-647 (Pubitemid 41503825)
24. Prato M, Gallo V, Giribaldi G, Arese P (2008) Phagocytosis of haemozoin (malarial pigment) enhances metalloproteinase-9 activity in human adherent monocytes: role of IL-1beta and 15-HETE. Malar J 157:8-17
25. Belnoue E, Potter SM, Rosa DS, Mauduit M, Grüner AC, Kayibanda M, Mitchell AJ, Hunt NH, Rénia L (2008) Control of pathogenic CD8+ T cell migration to the brain by IFN-gamma during experimental cerebral malaria. Parasite Immunol 30:544-553
26. Van den Steen PE, Deroost K, Van Aelst I, Geurts N, Martens E, Struyf S, Nie CQ, Hansen DS, Matthys P, Van Damme J, Opdenakker G (2008) CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Eur J Immunol 38:1082-1095
27. Brown H, Hien TT, Day N, Mai NT, Chuong LV, Chau TT, Loc PP, Phu NH, Bethell D, Farrar J, Gatter K, White N, Turner G (1999) Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 25:331-340 (Pubitemid 29392713)
28. Combes V, Coltel N, Faille D, Wassmer SC, Grau GE (2006) Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. Int J Parasitol 36:541-546 (Pubitemid 44275316)
29. Newton CRJC, Krishna S (1998) Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 79:1-53 (Pubitemid 28318261)
30. Clark IA, Rockett KA, Cowden WB (1992) Possible central role of nitric oxide in conditions clinically similar to cerebral malaria. Lancet 340:894-896
31. Newton CR, Hien TT, White N (2000) Cerebral malaria. J Neurol Neurosurg Psychiatry 69:433-441
32. Omari AA, Garner P (2007) Malaria: severe, life-threatening. Clin Evid (Online) July 2007, p 913
33. Helmers AJ, Gowda DC, Kain KC, Liles WC (2009) Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophages. Am J Trop Med Hyg 81:631-637
34. Piguet PF, Kan CD, Vesin C (2002) Role of the tumor necrosis factor receptor 2 (TNFR2) in cerebral malaria in mice. Lab Invest 82:1155-1166 (Pubitemid 35014849)
35. Awasthi G, Singh S, Dash AP, Das A (2008) Genetic characterization and evolutionary inference of TNF-alpha through computational analysis. Braz J Infect Dis 12:374-379
36. Randall LM, Engwerda CR (2010) TNF family members and malaria: old observations, new insights and future directions. Exp Parasitol 126:326-331
37. Togbe D, de Sousa PL, Fauconnier M, Boissay V, Fick L, Scheu S, Pfeffer K, Menard R, Grau GE, Doan BT, Beloeil JC, Renia L, Hansen AM, Ball HJ, Hunt NH, Ryffel B, Quesniaux VF (2008) Both functional LTbeta receptor and TNF receptor 2 are required for the development of experimental cerebral malaria. PLoS ONE 9:e2608
38. Amante FH, Haque A, Stanley AC, Rivera Fde L, Randall LM, Wilson YA, Yeo G, Pieper C, Crabb BS, de Koning-Ward TF, Lundie RJ, Good MF, Pinzon-Charry A, Pearson MS, Duke MG, McManus DP, Loukas A, Hill GR, Engwerda CR (2010) Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria. J Immunol 185:3632-3642
39. Jambou R, Combes V, Jambou MJ, Weksler BB, Couraud PO, Grau GE (2010) Plasmodium falciparum adhesion on human brain microvascular endothelial cells involves transmigration-like cup formation and induces opening of intercellular junctions. PLoS Pathog 29:e1001021
40. Lundie RJ, de Koning-Ward TF, Davey GM, Nie CQ, Hansen DS, Lau LS, Mintern JD, Belz GT, Schofield L, Carbone FR, Villadangos JA, Crabb BS, Heath WR (2008) Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. Proc Natl Acad Sci USA 105:14509-14514
41. Turner GD, Morrison H, Jones M, Davis TM, Looareesuwan S, Buley ID, Gatter KC, Newbold CI, Pukritayakamee S, Nagachinta B et al (1994) An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 145:1057-1069 (Pubitemid 24345654)
42. Dietrich JB (2002) The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J Neuroimmunol 128:58-68
43. Favre N, Da Laperousaz C, Ryffel B, Weiss NA, Imhof BA, Rudin W, Lucas R, Piguet PF (1999) Role of ICAM-1 (CD54) in the development of murine cerebral malaria. Microbes Infect 1:961-968
44. Ockenhouse CF, Betageri R, Springer TA, Staunton DE (1992) Plasmodium falciparum-infected erythrocytes bind ICAM-1 at a site distinct from LFA-1, Mac-1, and human rhinovirus. Cell 68:63-69
45. Rénia L, Potter SM, Mauduit M, Rosa DS, Kayibanda M, Deschemin JC, Snounou G, Grüner AC (2006) Pathogenic T cells in cerebral malaria. Int J Parasitol 36:547-554
46. Wassmer SC, Cianciolo GJ, Combes V, Grau GE (2005) Inhibition of endothelial activation: a new way to treat cerebral malaria? PLoS Med 2:e245
47. Monso-Hinard C, Lou JN, Behr C, Juillard P, Grau GE (1997) Expression of major histocompatibility complex antigens on mouse brain microvascular endothelial cells in relation to susceptibility to cerebral malaria. Immunology 92:53-59 (Pubitemid 27380881)
48. Chen L, Zhang Z, Sendo F (2000) Neutrophils play a critical role in the pathogenesis of experimental cerebral malaria. Clin Exp Immunol 120:125-133 (Pubitemid 30176909)
49. Chen L, Sendo F (2001) Cytokine and chemokine mRNA expression in neutrophils from CBA/NSlc mice infected with Plasmodium berghei ANKA that induces experimental cerebral malaria. Parasitol Int 50:139-143 (Pubitemid 32600949)
50. Korthuis RJ, Anderson DC, Granger DN (1994) Role of neutrophil- endothelial cell adhesion in inflammatory disorders. J Crit Care 9:47-71 (Pubitemid 24095050)
51. Pais TF, Chatterjee S (2005) Brain macrophage activation in murine cerebral malaria precedes accumulation of leukocytes and CD8+ T cell proliferation. J Neuroimmunol 163:73-83 (Pubitemid 40692950)
52. Szklarczyk A, Stins M, Milward EA, Ryu H, Fitzsimmons C, Sullivan D, Conant K (2007) Glial activation and matrix metalloproteinase release in cerebral malaria. J Neurovirol 3:2-10
53. Kurtzhals JA, Reimert CM, Tette E, Dunyo SK, Koram KA, Akanmori BD, Nkrumah FK, Hviid L (1998) Increased eosinophil activity in acute Plasmodium falciparum infection - association with cerebral malaria. Clin Exp Immunol 112:303-307 (Pubitemid 28266691)
54. Waters LS, Taverne J, Tai PC, Spry CJ, Targett GA, Playfair JH (1987) Killing of Plasmodium falciparum by eosinophil secretory products. Infect Immun 55:877-881 (Pubitemid 17035420)
55. Camacho LH, Wilairatana P, Weiss G, Mercader MA, Brittenham GM, Looareesuwan S, Gordeuk VR (1999) The eosinophilic response and haematological recovery after treatment for Plasmodium falciparum malaria. Trop Med Int Health 4:471-475 (Pubitemid 29369897)
56. Good MF, Currier J (1992) The importance of T cell homing and the spleen in reaching a balance between malaria immunity and immunopathology: the moulding of immunity by early exposure to cross-reactive organisms. Immunol Cell Biol 70:405-410 (Pubitemid 23032827)
57. Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, Potter S, Medana IM, Miu J, Ball HJ (2006) Immunopathogenesis of cerebral malaria. Int J Parasitol 36:569-582 (Pubitemid 43674512)
58. Amante FH, Stanley AC, Randall LM, Zhou Y, Haque A, McSweeney K, Waters AP, Janse CJ, Good MF, Hill GR, Engwerda CR (2007) A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol 171:548-559 (Pubitemid 47344687)
59. Suidan GL, Mcdole JR, Chen Y, Pirko I, Johnson AJ (2008) Induction of blood brain barrier tight junction protein alterations by CD8 T cells. PLoS ONE 22:e3037
60. Medana IM, Hunt NH, Chan-Ling T (1997) Early activation of microglia in the pathogenesis of fatal murine cerebral malaria. Glia 19:91-103 (Pubitemid 27098815)
61. Medana IM, Hunt NH, Chaudhri G (1997) Tumor necrosis factor-alpha expression in the brain during fatal murine cerebral malaria: evidence for production by microglia and astrocytes. Am J Pathol 150:1473-1486 (Pubitemid 27152664)
62. Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, Crabb BS, Heath WR, Engwerda CR, Hickey MJ, Schofield L, Hansen DS (2009) IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog 5(4):e1000369
63. Rudin W, Eugster HP, Bordmann G, Bonato J, Müller M, Yamage M, Ryffel B (1997) Resistance to cerebral malaria in tumor necrosis factor-alpha/beta-deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response. Am J Pathol 150(1):257-266 (Pubitemid 27027115)
64. Bachmann MF, Schwarz K, Wolint P, Meijerink E, Martin S, Manolova V, Oxenius A (2004) Distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+T cells. J Immunol 173:2217-2221 (Pubitemid 39063073)
65. Potter S, Chan-Ling T, Ball HJ, Mansour H, Mitchell A, Maluish L, Hunt NH (2006) Perforin mediated apoptosis of cerebral microvascular endothelial cells during experimental cerebral malaria. Int J Parasitol 36:485-496 (Pubitemid 43728781)
66. Wassmer SC, Combes V, Candal FJ, Juhan-Vague I, Grau GE (2006) Platelets potentiate brain endothelial alterations induced by Plasmodium falciparum. Infect Immun 74:645-653 (Pubitemid 43023120)
67. Couper KN, Barnes T, Hafalla JC, Combes V, Ryffel B, Secher T, Grau GE, Riley EM, de Souza JB (2010) Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. PLoS Pathog 29:e1000744
68. Pino P, Vouldoukis I, Dugas N, Hassani-Loppion G, Dugas B, Mazier D (2003) Redox-dependent apoptosis in human endothelial cells after adhesion of Plasmodium falciparum-infected erythrocytes. Ann NY Acad Sci 1010:582-586 (Pubitemid 38265050)
69. Paterniti I, Esposito E, Mazzon E, Galuppo M, Di Paola R, Bramanti P, Kapoor A, Thiemermann C, Cuzzocrea S (2010) Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther 333:465-477
70. Lopansri BK, Anstey NM, Weinberg JB, Stoddard GJ, Hobbs MR, Levesque MC, Mwaikambo ED, Granger DL (2003) Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet 361:676-678 (Pubitemid 36246553)
71. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, SingelDJ, Stamler JS (1993)Aredox-basedmechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364:626-632 (Pubitemid 23274719)
72. Machado FS, Desruisseaux MS, Nagajyothi, Kennan RP, Hetherington HP, Wittner M, Weiss LM, Lee SC, Scherer PE, Tsuji M, Tanowitz HB (2006) Endothelin in a murine model of cerebral malaria. Exp Biol Med Maywood 231:1176-1181 (Pubitemid 43845600)
73. Enwonwu CO, Afolabi BM, Salako LO, Idigbe EO, Bashirelah N (2000) Increased plasma levels of histidine and histamine in falciparum malaria: relevance to severity of infection. J Neural Transm 107:1273-1287
74. Noedl H, Youry Se, Schaecher K, Smith BL, Socheat D, Fukuda MM (2008) Evidence of artemisinin-resistant malaria in Western Cambodia . N Engl J Med 359;24. www.nejm.org. http://content.nejm.org/cgi/reprint/359/24/2619.pdf. Accessed 24 November 2010
75. Jensen M, Mehlhorn H (2009) Seventy-five years of Resochin® in the fight against malaria. Parasitol Res 105:609-627
76. WHO (2009) World malaria report 2009. WHO, Geneva. http://www.who.int/ malaria/world-malaria-report-2009/en/index.html. Accessed 24 November 2010
77. Meremikwu MM, Marson AG (2002) Routine anticonvulsants for treating cerebral malaria. Cochrane Database Syst Rev 2: CD002152
78. Panisko DM, Keystone JS (1990) Treatment of malaria - 1990. Drugs 39:160-189 (Pubitemid 120032391)
79. WHO (2005) World malaria report, 2005. WHO, Geneva
80. WHO (2010) Guidelines for the treatment of malaria - 2nd edition. WHO, Geneva
81. Committee to Advice on Tropical Medicine and Travel (1995) Canadian recommendations for the prevention and treatment of malaria among international travellers. CCDR 21S3:1-18
82. Waknine-Grinberg JH, Hunt N, Bentura-Marciano A, McQuillan JA, Chan HW, Chan WC, Barenholz Y, Haynes RK, Golenser J (2010) Artemisone effective against murine cerebral malaria. Malar J 9:227
83. Zamidei L, Durval A, Bettocchi D, Luzzio MG, Bartoloni A, Consales G (2010) Efficacy and safety of quinine-artesunate in an HIV-positive patient with severe falciparum malaria. Minerva Anestesiol 76:66-69
84. Lackner P, Part A, Burger C, Dietmann A, Broessner G, Helbok R, Reindl M, Schmutzhard E, Beer R (2009) Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study. Malar J 27:8-36
85. Muniz-Junqueira MI (2007) Immunomodulatory therapy associated to anti-parasite drugs as a way to prevent severe forms of malaria. Curr Clin Pharmacol 2:59-73
86. Chowdhury K, Bagasra O (2007) An edible vaccine for malaria using transgenic tomatoes of varying sizes, shapes and colors to carry different antigens. Med Hypotheses 68:22-30 (Pubitemid 44692051)
87. Jirage D, Keenan SM, Waters NC (2010) Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases. Infect Disord Drug Targets 10(3):134-146
88. Donaldson T, Kim K (2010) Targeting Plasmodium falciparum purine salvage enzymes: a look at structure-based drug development. Infect Disord Drug Targets 10(3):191-199
89. Allan RJ, Beattie P, Bate C, Van Hensbroek MB, Morris-Jones S, Greenwood BM, Kwiatkowski D (1995) Strain variation in tumor necrosis factor induction by parasites from children with acute falciparum malaria. Infect Immun 63:1173-1175
90. Sanchez CP, Dave A, Stein WD, Lanzer M (2010) Transporters as mediators of drug resistance in Plasmodium falciparum. Int J Parasitol. doi:10.1016/j.ijpara.2010.04.001
91. Bloland PB (2001) Drug resistance in malaria. World Health Organization, Geneva, 534 WHO/CDC/DRS/2001.4
92. World Health Organization (2006) Guidelines for the treatment of malaria. WHO, Geneva
93. Talisuna AO, Bloland P, D'Alessandro U (2004) History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 17:235-254 (Pubitemid 38120936)
94. Jackson Y, Chappuis F, Loutan L, Taylor W (2006) Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure?Malar J 5:81. doi:10.1186/1475-2875-5-81
95. Laufer M, Thesing P, Eddington N, Masonga R, Dzinjalamala F, Takala S, Taylor T, Plowe C (2006) Return of chloroquine antimalarial efficacy in Malawi. N Eng J Med 355:1959-1966 (Pubitemid 44708015)
96. Osei-Akoto A, Orton L, Owusu-Ofori SP (2005) Atovaquoneproguanil for treating uncomplicated malaria. Cochrane Database Syst Rev 19:CD004529
97. White NJ (2007) Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7:549-558
98. Wiwanitkit V (2009) Headache and malaria: a brief review. Acta Neurol Taiwan 18:56-59
99. Vedy J, Graveline J, Carrica J, Rivaud C, Chanut G (1979) Retinopathy due to 4- aminoquinolines in the prevention of malaria. Bull Soc Pathol Exot Filiales 72:353-357 (Pubitemid 10067241)
100. Bertagnolio S, Tacconelli E, Camilli G, Tumbarello M (2001) Case report: Retinopathy after malaria prophylaxis with chloroquine. Am J Trop Med Hyg 65:637-638 (Pubitemid 33134605)
101. Phillips-Howard PA, Wood D (1996) The safety of antimalarial drugs in pregnancy. Drug Saf 14:131-145 (Pubitemid 26086050)
102. Mérat S, Lambert E, Vincenti-Rouquette I, Gidenne S, Rousseau JM, Brinquin L (2003) Case report: combination artemetherlumefantrine and haemolytic anaemia following a malarial attack. Trans R Soc Trop Med Hyg 97:433-434 (Pubitemid 39186026)
103. Busari O, Busari O (2008) Ventricular fibrillation in a 5-year-old child on therapeutic dose of quinine dihydrochloride infusion for acute malaria. J Natl Med Assoc 100:1063-1065
104. Singhi S, Singhi P, Singh M (1979) Extrapyramidal syndrome following chloroquine therapy. Indian J Pediatr 46:58-60 (Pubitemid 9201969)
105. Busari OA, Oligbu G (2008) Chorea in a 29-year-old Nigerian following antimalarial treatment with artesunate. Int J Infect Dis 12:221-223
106. Gürkov R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, Krause E, Schmidt M, Hempel JM, Löscher T (2008) Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J 7:179
107. Leroy F, Bridoux F, Abou-Ayache R, Belmouaz S, Desport E, Thierry A, Bauwens M, Touchard G (2008) Quinine-induced renal bilateral cortical necrosis. Néphrol Thér 4:181-186
108. Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ, d'Alessandro U, Modiano D (2008) High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS ONE 3:e4031
109. Gupta GB, Varma S (2001) Effect of intravenous quinine on capillary glucose levels in malaria. J Assoc Physicians India 49:426-429 (Pubitemid 33641643)
110. Dyan AD (1998) Neurotoxicity and artemisinin compounds do the observations in animals justify limitation of clinical use? Med Trop Mars 58:32-37
111. Nosten F, McGready R, d'Alessandro U, Bonell A, Verhoeff F, Menendez C, Mutabingwa T, Brabin B (2006) Antimalarial drugs in pregnancy: a review. Curr Drug Saf 1:1-15
112. Smith HJ, Meremikwu M (2003) Iron chelating agents for treating malaria. Cochrane Database Syst Rev 2:CD001474
113. Bukirwa H, Garner P, Critchley J (2004) Chlorproguanil-dapsone for treating uncomplicated malaria. Cochrane Database Syst Rev 18:CD004387
114. Waknine-Grinberg JH, McQuillan JA, Hunt N, Ginsburg H, Golenser J (2010) Modulation of cerebral malaria by fasudil and other immune-modifying compounds. Exp Parasitol 125(2):141-146
115. Wang YX (2010) PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res 20:124-137
116. Straus DS, Glass CK (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28:551-558 (Pubitemid 350101420)
117. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52 (Pubitemid 32095641)
118. Maeda T, Kishioka S (2009) PPAR and pain. Int Rev Neurobiol 85:165-177
119. Kostadinova R, Wahli W, Michalik L (2005) PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 12:2995-3009 (Pubitemid 41672488)
120. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435 (Pubitemid 34177889)
121. Gelinas DS, McLaurin J (2005) PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats. Neurochem Res 2005:1369-1375 (Pubitemid 41784472)
122. Lee JH, Joe EH, Jou I (2005) PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. NeuroReport 16:829-833 (Pubitemid 40733794)
123. Collino M, Patel NS, Thiemermann C (2005) PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis 2:179-197
124. Feng D, Zhang Y, Chen G (2008) Cortical expression of peroxisome proliferator-activated receptor-alpha after human brain contusion. J Int Med Res 36:783-791
125. Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C (2005) Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts europrotective effects in traumatic brain injury. Neurosci Lett 388:7-12 (Pubitemid 41569361)
126. Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C (2007) Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 24:1119-1131 (Pubitemid 47106286)
127. Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R (2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264-6271 (Pubitemid 36875628)
128. Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK Activation of peroxisome proliferatoractivated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology 58(2):337-345
129. Serghides L, Kain KC (2001) Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. J Immunol 166:6742-6748 (Pubitemid 32467218)
130. Klotz L, Diehl L, Dani I, Neumann H, von Oppen N, Dolf A, Endl E, Klockgether T, Engelhardt B, Knolle P (2007) Brain endothelial PPARgamma controls inflammation-induced CD4+ T cell adhesion and transmigration in vitro. J Neuroimmunol 190:34-43 (Pubitemid 47625605)
131. Sun H, Huang Y, Yu X, Li Y, Yang J, Li R, Deng Y, Zhao G (2008) Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats. Int J Dev Neurosci 26:505-515
132. Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813-1826 (Pubitemid 351599735)
133. García-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC (2005) Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 57:885-894 (Pubitemid 40488357)
134. Wang CX, Ding X, Noor R, Pegg C, He C, Shuaib A (2009) Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J Cereb Blood Flow Metab 29:1683-1694
135. Hyong A, Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813-1826 (Pubitemid 351599735)
136. Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, Tang J (2008) Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 1215:218-224
137. Bernardo A, Minghetti L (2008) Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008:864-140
138. Kumari R, Willing LB, Patel SD, Krady JK, Zavadoski WJ, Gibbs EM, Vannucci SJ, Simpson IA (2010) The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab 30:352-360
139. Malchiodi-Albedi F, Matteucci A, Bernardo A, Minghetti L (2008) PPAR-gamma, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches. PPAR Res 2008:295-784
140. Boggild AK, Krudsood S, Patel SN, Serghides L, Tangpukdee N, Katz K, Wilairatana P, Liles WC, Looareesuwan S, Kain KC (2009) Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 49:841-849
141. Bernardo A, Bianchi D, Magnaghi V, Minghetti L (2009) Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells. J Neuropathol Exp Neurol 68:97-808
142. Sundararajan S, Jiang Q, Heneka M, Landreth G (2006) PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 49:136-144 (Pubitemid 43867071)
143. Kwak H, Hwang I, Kim JH, Kim MY, Yang JS, Jeong S (2009) Modulation of transcription by the peroxisome proliferator-activated receptor β/γ-binding RNA aptamer in colon cancer cells. Mol Cancer Ther 8:2664-2673
144. Piqueras L, Sanz MJ, Perretti M, Morcillo E, Norling L, Mitchell JA, Li Y, Bishop-Bailey D (2009) Activation of PPAR /β/δ inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol 86:115-122
145. al Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J (2008) PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 128:1940-1949
146. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D (2007) Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27:63-69 (Pubitemid 46370477)
147. Ding G, Cheng L, Qin Q, Frontin S, Yang Q (2006) PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 40:821-828 (Pubitemid 43817042)
148. Tan NS, Michalik L, Di-Poï N, Ng CY, Mermod N, Roberts AB, Desvergne B, Wahli W (2004) Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression. EMBO J 23:4211-4221 (Pubitemid 39546159)
149. Galuppo M, di Paola R, Mazzon E, Genovese T, Crisafulli C, Paterniti I, Cuzzocrea E, Bramanti P, Kapoor A, Thiemermann C, Cuzzocrea S (2010) Role of PPAR-β/δ in the development of zymosan-induced multiple organ failure: an experiment mice study. J Inflamm Lond 18:7-12
150. Kalinin S, Richardson JC, Feinstein DL (2009) A PPAR β/δ agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 6:431-437
151. Haskova Z, Hoang B, Luo G, Morgan LA, Billin AN, Barone FC, Shearer BG, Barton ME, Kilgore KS (2008) Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPAR /β/δ ligand GW0742. Inflamm Res 57:314-321
152. Defaux A, Zurich MG, Braissant O, Honegger P, Monnet-Tschudi F (2009) Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination. J Neuroinflammation 7:6-15
153. Rodríguez-Calvo R, Serrano L, Coll T, Moullan N, Sánchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vázquez-Carrera M (2008) Activation of peroxisome proliferator-activated receptor â/ä inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 57:2149-2157
154. Tripathi AK, Sha W, Shulaev V, Stins MF, Sullivan DJ Jr (2009) Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. Blood 114:4243-4252
155. Lim HJ, Park JH, Lee S, Choi HE, Lee KS, Park HY (2009) PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. Eur J Pharmacol 622:45-51
156. Sheng L, Ye P, Liu YX, Han CG, Zhang ZY (2008) Peroxisome proliferator-activated receptor â/ä activation improves angiotensin II-induced cardiac hypertrophy in vitro. Clin Exp Hypertens 30:109-119 (Pubitemid 351302225)
157. Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ (2010) Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130 (4):572-588
158. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303-308 (Pubitemid 34060358)
159. Schug TT, Li X (2009) PPAR delta-mediated macrophage activation: a matter of fat. Dis Model Mech 10:421-422
160. Barish GD, Atkins AR, Downes M, Olson P, Chong LW, NelsonM, Zou Y, Hwang H, Kang H, Curtiss L, Evans RM, Lee CH (2008) PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 105:4271-4276 (Pubitemid 351754370)
161. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, Hsueh WA, Tangirala RK (2008) PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 105:4277-4282 (Pubitemid 351754371)
162. Kim HJ, Kim MY, Jin H, Kim HJ, Kang SS, Kim HJ, Lee JH, Chang KC, Hwang JY, Yabe-Nishimura C, Kim JH, Seo HG (2009) Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta} 1/Smad3. Circ Res 105:16-24
163. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA (2006) Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J 20:326-328 (Pubitemid 46671159)
164. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA (2006) Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 34:242-246 (Pubitemid 43202472)
165. Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, Clarke AR (2004) PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23:8992-8996 (Pubitemid 39657790)
166. Mukundan L, Odegaard JI, Morel CR, Heredia JE, Mwangi JW, Ricardo-Gonzalez RR, Goh YP, Eagle AR, Dunn SE, Awakuni JU, Nguyen KD, Steinman L, Michie SA, Chawla A (2009) PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med 15:1266-1272
167. Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, Isom HC, Perdew GH, Gonzalez FJ, Peters JM (2008) Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/γ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci 105:418-428
168. Cabrales P, Zanini GM, Meays D, Frangos JA, Carvalho LJ (2010) Murine cerebral malaria is associated with a vasospasm-like microcirculatory dysfunction, and survival upon rescue treatment is markedly increased by nimodipine. Am J Pathol 176:1306-1315
169. Hall MG, Quignodon L, Desvergne B (2008) Peroxisome proliferator- activated receptor /β/δ in the brain: facts and hypothesis. PPAR Res 2008(2008):780452
170. Coll T, Rodrïguez-Calvo R, Barroso E, Serrano L, Eyre E, Palomer X, Vázquez-Carrera M (2009) Peroxisome proliferator-activated receptor (PPAR) /β/δ: a new potential therapeutic target for the treatment of metabolic syndrome. Curr Mol Pharmacol 2:46-55
171. Erol A (2005) PPARalpha activators may be good candidates as anti-aging agents. Med Hypotheses 65:35-38
172. Huang TH, Teoh AW, Lin BL, Lin DS, Roufogalis B (2009) The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol Res 60:195-206